Established in 1982. Makers of generic medicines. Alphapharm is the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme. Operates a manufacturing plant in Queensland. Acquired by Mylan in 2007. Bought Aspen's portfolio of prescription and over-the-counter products in Australia for $188 million in 2019.
|Alphapharm Pty Ltd||AUS||website|
| Mylan NV
owns 100% of Alphapharm Pty Ltd
|Alphapharm Pty Ltd|
Signatory to the Australian Packaging Covenant, a voluntary agreement to encourage waste minimisation.
Source: Australian Packaging Covenant (2020)
According to data released by the Australian Tax Office in Dec 2018, this company was one of 2,159 local and foreign-based companies that paid no tax in Australia in 2016-17. Please note however that companies pay income tax on profits, not revenue (total income). While some companies use tax havens and loopholes to avoid paying their fair share of tax in Australia, other companies that paid no tax have perfectly legitimate reasons.
Source: ATO (2018)
In 2019, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of B.
Source: CDP (2019)
In 2019, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security Score of B-.
Source: CDP (2019)
This company received a score of 20.2/100 in the Newsweek Green Rankings 2016, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
Source: Newsweek (2016)
In August 2017, Mylan agreed to a $465 million settlement in a whistleblower lawsuit. The U.S. Justice Department and several states claimed the company overcharged Medicaid for EpiPens. As part of the settlement, Mylan did not have to admit any wrongdoing. The settlement came as Mylan faced growing complaints about skyrocketing price hikes for EpiPens. Between 2007 and 2016, Mylan increased the price of a two-pack of EpiPens from less than $100 to more than $600.
Source: Drug Watch (2017)
This company received an S&P Global ESG Score of 19/100 in the Pharmaceuticals category of the 2019 SAM Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices. The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2019)
In 2019 the median pay for a worker at this company was US$43,367. The CEO was paid 427 times this amount. Exorbitant CEO pay is a major contributor to rising inequality. CEOs are getting more because of their power to set pay, not because they are increasing productivity or possess specific, high-demand skills. The economy would suffer no harm if CEOs were paid less (or taxed more). In contrast, the CEO-to-typical-worker compensation ratio was 20-to-1 in 1965 and 58-to-1 in 1989.
Source: AFL-CIO (2020)
Mylan, the makers of the EpiPen, an injectable device that is filled with medicine and can stop a life-threatening allergic reaction with immediate effect, have increased the price of the device from $100 in 2008 to above $500 in 2016, making it a hike of over 400 per cent. Epipens only cost a few dollars to make and the price-hike has caused a public outcry.
Source: news article (2016)
As You Sow's 2020 report, 'The 100 Most Overpaid CEOs', reveals the 100 most overpaid CEOs from USA's 500 largest public companies (as determined by the S&P 500 list). This company's CEO, Heather Bresch came in at number 64 on the list, having been paid US$13,332,368 in 2019. According to the report, "Most CEOs have come to be grossly overpaid, and that overpayment is harmful to the companies, the shareholders, the customers, the other employees, the economy, and society as a whole."
Source: As You Sow (2020)
California, the UK and Australia have all enacted legislation requiring companies operating within their borders to disclose their efforts to eradicate modern slavery from their operations and supply chains. Follow the link to see this company's disclosure statement.
Source: Modern Slavery Registry (2016)
JUST Capital polls Americans every year to identify the issues that matter most in defining just business behaviour. For their 2021 rankings the public identified 19 issues, which are organised under the headings Workers, Communities, Customers, Shareholders and Environment. JUST Capital then define metrics that map to those issues and track and analyse the largest, publicly traded U.S. companies. This analysis powers their rankings, in which this company ranked 295th of 928 companies, and 14th of 51 Pharmaceuticals & Biotech companies.
Source: JUST Capital (2020)
OpenSecrets.org tracks the influence of money on U.S. politics, and how that money affects policy and citizens' lives. Follow link to see this company's record of political donations, lobbying, outside spending and more.
Source: Open Secrets (2014)
|Employees||640 in 2017|
|Address||Level 1, 30 The Bond, 30-34 Hickson Rd, Millers Point, NSW, 2000, Australia|
|Phone||02 9298 3999|
|Fax||02 9566 4686|
Products / BrandsMylan Australia
Dermeze Skin Care
Dermeze Bodywash/Shower Gel
Dymadon Pain Relief Tablets
Gastro-Stop Digestive Care
Irish Moss Cold & Flu
Tums Digestive Care
Waxsol Eye & Ear Care
Zantac Digestive Care